Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae

identification and Sanger sequencing for FC428 strain tracking. For predicting decreased-susceptibility strains with A501 mutations, MIRCA achieved 98.33% agreement with Sanger sequencing. Simulated tests demonstrated 100% consistency between MIRCA results in centrifuge tubes and microfluidic chips. This robust and cost-effective approach addresses current challenges in AMR surveillance. Its integration with microfluidic chip offers an affordable and user-friendly diagnostic solution, making it highly valuable for timely infectious disease diagnosis and resistance monitoring. It also holds significant potential for point-of-care testing in resource-limited areas.